SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Invesco Ltd.

(Last) (First) (Middle)
1555 PEACHTREE STREET NE
SUITE 1800

(Street)
ATLANTA GA 30309

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Evofem Biosciences, Inc. [ EVFM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2020
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 05/14/2020 J(1) 78,013 A $5.13 12,446,479 I See Footnotes 1
Common stock 05/15/2020 S 3,211 D $5.04 12,443,268 I See Footnotes 1
Common stock 05/26/2020 S 73,814 D $5.79 12,369,454 I See Footnotes 1
Common stock 05/26/2020 S 65 D $5.98 12,369,389 I See Footnotes 1
Common stock 06/05/2020 P(2)(3) 857,143 A $3.5 13,226,532 I See Footnotes 2
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Invesco Ltd. acquired the following common shares through its affiliates in a spin off transaction (the "Spin Off Transaction") on May 14, 2020: Invesco FTSE RAFI US 1500 Small-Mid ETF (73,814 shares of common stock); Invesco Buyback Achievers ETF (3,257 shares of common stock); LongView Broad Market 3000 Index Fund (Amalgamated) (923 shares of common stock); and Invesco Purebeta MSCI USA Small Cap ETF (19 shares of common stock). On May 15, 2020 the Invesco Buyback Achievers ETF sold 3,211 shares of Common Stock. On May 26, 2020, the Invesco FTSE RAFI US 1500 Small-Mid ETF sold 73,814 shares of Common Stock, the Invesco Buyback Achievers ETF sold 46 shares of Common Stock and the Invesco Purebeta MSCI USA Small Cap ETF sold 19 shares.
2. On June 5, 2020, Invesco Ltd., through its affiliates, the Invesco High Income Fund (UK) and the Invesco Income Fund (UK), purchased 589,302 and 267,841, respectively, of the Issuer's common stock at a price of $3.50 per share as part of the Issuer's registered public offering of 28,500,000 shares.
3. Invesco Ltd. is aware that, under Section 16(b) of the Securities and Exchange Act of 1934, as amended, certain of the sales are matachable against certain purchases of Common Stock. Invesco Ltd. has calculated the aggregate profit to be $174,140.20, using the lowest possible purchase prices and the highest possible sales prices for such trades, and accordingly intends to remit payment to the Company in that amount less transaction costs.
Remarks:
Robert Leveille, Global Assurance Officer 06/09/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.